NCT02085070View on ClinicalTrials.gov

MK-3475 in Melanoma and NSCLC Patients With Brain Metastases

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

February 27, 2020

Study Completion Date

February 27, 2020

Conditions
MelanomaNon-Small Cell Lung CancerBrain Metastases
Interventions
DRUG

MK-3475

IV MK-3475

Trial Locations (1)

06510

Smilow Cancer Center at Yale New Haven Hospital, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT02085070 - MK-3475 in Melanoma and NSCLC Patients With Brain Metastases | Biotech Hunter | Biotech Hunter